Therapeutic strategies for COVID-19: progress and lessons learned
G Li, R Hilgenfeld, R Whitley, E De Clercq - Nature Reviews Drug …, 2023 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
The SARS‐CoV‐2 main protease (Mpro): Structure, function, and emerging therapies for COVID‐19
Q Hu, Y Xiong, GH Zhu, YN Zhang, YW Zhang… - MedComm, 2022 - Wiley Online Library
The main proteases (Mpro), also termed 3‐chymotrypsin‐like proteases (3CLpro), are a
class of highly conserved cysteine hydrolases in β‐coronaviruses. Increasing evidence has …
class of highly conserved cysteine hydrolases in β‐coronaviruses. Increasing evidence has …
SARS-CoV-2 main protease drug design, assay development, and drug resistance studies
Conspectus SARS-CoV-2 is the etiological pathogen of the COVID-19 pandemic, which led
to more than 6.5 million deaths since the beginning of the outbreak in December 2019. The …
to more than 6.5 million deaths since the beginning of the outbreak in December 2019. The …
Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review
Severe acute respiratory syndrome-associated coronavirus (SARS-CoV) identified in 2003
infected∼ 8000 people in 26 countries with 800 deaths, which was soon contained and …
infected∼ 8000 people in 26 countries with 800 deaths, which was soon contained and …
SARS-CoV-2 antiviral therapy
The development of effective antiviral therapy for COVID-19 is critical for those awaiting
vaccination, as well as for those who do not respond robustly to vaccination. This review …
vaccination, as well as for those who do not respond robustly to vaccination. This review …
Development of highly potent noncovalent inhibitors of SARS-CoV-2 3CLpro
The 3C-like protease (3CLpro) is an essential enzyme for the replication of SARS-CoV-2
and other coronaviruses and thus is a target for coronavirus drug discovery. Nearly all …
and other coronaviruses and thus is a target for coronavirus drug discovery. Nearly all …
[HTML][HTML] Inhibition of the main protease of SARS-CoV-2 (Mpro) by repurposing/designing drug-like substances and utilizing nature's toolbox of bioactive compounds
I Antonopoulou, E Sapountzaki, U Rova… - Computational and …, 2022 - Elsevier
The emergence of the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)
has resulted in a long pandemic, with numerous cases and victims worldwide and enormous …
has resulted in a long pandemic, with numerous cases and victims worldwide and enormous …
A multi-pronged evaluation of aldehyde-based tripeptidyl main protease inhibitors as SARS-CoV-2 antivirals
As an essential enzyme of SARS-CoV-2, the COVID-19 pathogen, main protease (M Pro) is
a viable target to develop antivirals for the treatment of COVID-19. By varying chemical …
a viable target to develop antivirals for the treatment of COVID-19. By varying chemical …
Phenylpyrazolone-1, 2, 3-triazole hybrids as potent antiviral agents with promising SARS-CoV-2 main protease inhibition potential
COVID-19 infection is now considered one of the leading causes of human death. As an
attempt towards the discovery of novel medications for the COVID-19 pandemic, nineteen …
attempt towards the discovery of novel medications for the COVID-19 pandemic, nineteen …
Penicillin derivatives inhibit the SARS-CoV-2 main protease by reaction with its nucleophilic cysteine
TR Malla, L Brewitz, DG Muntean… - Journal of medicinal …, 2022 - ACS Publications
The SARS-CoV-2 main protease (Mpro) is a medicinal chemistry target for COVID-19
treatment. Given the clinical efficacy of β-lactams as inhibitors of bacterial nucleophilic …
treatment. Given the clinical efficacy of β-lactams as inhibitors of bacterial nucleophilic …